Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 451381 - 451400 out of 495978 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Sweden | (L01EA06) asciminib (adm: O) | Scemblix | 60, 40 mg , Blister, 60 tabletter | Retail price without vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisSverigeAB |
| Sweden | (L01ED05) lorlatinib (adm: O) | Lorviqua | 30, 100 mg , Blister, 30 tabletter | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | PfizerAB |
| Sweden | (L01ED05) lorlatinib (adm: O) | Lorviqua | 90, 25 mg , Blister, 90 tabletter | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | PfizerAB |
| Sweden | (L01XH03) panobinostat | Farydak | 6, 10 mg , Blister, 6 kapslar | Retail price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | GHNPharmaNordicAB |
| Sweden | (L01XH03) panobinostat | Farydak | 6, 15 mg , Blister, 6 kapslar | Retail price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | GHNPharmaNordicAB |
| Sweden | (L01XH03) panobinostat | Farydak | 6, 20 mg , Blister, 6 kapslar | Retail price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | GHNPharmaNordicAB |
| Sweden | (L02AE01) buserelin | Suprefact® | 11, 1 mg/ml , Injektionsflaska, 2 x 5,5 ml | Retail price without vat |
$0-0 |
$0-0 |
n/a | CheplapharmArzneimittelGmbH |
| Sweden | (L02AE01) buserelin | Suprefact® Depot | 1, 6,3 mg , Förfylld spruta, 1 st | Retail price without vat |
$0-0 |
$0-0 |
n/a | CheplapharmArzneimittelGmbH |
| Sweden | (L02AE01) buserelin | Suprefact® Depot | 1, 9,45 mg , Förfylld spruta, 1 st | Retail price without vat |
$0-0 |
$0-0 |
n/a | CheplapharmArzneimittelGmbH |
| Sweden | (L02AE01) buserelin | Suprecur® | 200, 0,15 mg/dos , Flaska, 2 x 100 doser | Retail price without vat |
$0-0 |
$0-0 |
n/a | CheplapharmArzneimittelGmbH |
| Sweden | (L02AE03) goserelin (adm: implant) | Zoladex | 1, 3,6 mg , Implantat, förfylld spruta, 1 x 3,6 mg | Retail price without vat |
$0-0 |
$0-0 |
n/a | AbacusMedicineA/S |
| Sweden | (L03AA02) filgrastim (adm: P) | Nivestim | 5, 12 ME/0,2 ml , Förfylld spruta, 5 st | Retail price without vat |
$0-0 |
$0-0 |
Hematopoietic Stem Cell Transplantation;Cancer | PfizerAB |
| Sweden | (L03AA02) filgrastim (adm: P) | Nivestim | 5, 30 ME/0,5 ml , Förfylld spruta, 5 st | Retail price without vat |
$0-0 |
$0-0 |
Hematopoietic Stem Cell Transplantation;Cancer | PfizerAB |
| Sweden | (L03AA02) filgrastim (adm: P) | Nivestim | 8, 30 ME/0,5 ml , Förfylld spruta, 8 st | Retail price without vat |
$0-0 |
$0-0 |
Hematopoietic Stem Cell Transplantation;Cancer | PfizerAB |
| Sweden | (L03AA02) filgrastim (adm: P) | Nivestim | 5, 48 ME/0,5 ml , Förfylld spruta, 5 st | Retail price without vat |
$0-0 |
$0-0 |
Hematopoietic Stem Cell Transplantation;Cancer | PfizerAB |
| Sweden | (L03AA02) filgrastim (adm: P) | Nivestim | 8, 48 ME/0,5 ml , Förfylld spruta, 8 st | Retail price without vat |
$0-0 |
$0-0 |
Hematopoietic Stem Cell Transplantation;Cancer | PfizerAB |
| Sweden | (L03AA13) pegfilgrastim (adm: P) | Fulphila | 1, 6 mg , Förfylld spruta, 1 st, med automatiskt nålskydd | Retail price without vat |
$0-0 |
$0-0 |
n/a | BioconBiologicsFinlandOy |
| Sweden | (L04AC10) secukinumab (adm: P) | Cosentyx | 2, 150 mg , Förfylld spruta, 2 st | Retail price without vat |
$0-0 |
$0-0 |
Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing | NovartisSverigeAB |
| Sweden | (L04AC10) secukinumab (adm: P) | Cosentyx | 1, 300 mg , Förfylld injektionspenna, 1 st | Retail price without vat |
$0-0 |
$0-0 |
Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing | NovartisSverigeAB |
| Sweden | (L04AC10) secukinumab (adm: P) | Cosentyx | 1, 75 mg , Förfylld spruta, 1 st, med automatiskt nålskydd | Retail price without vat |
$0-0 |
$0-0 |
Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing | NovartisSverigeAB |
Pages
